Publications by authors named "Licia Denti"

Article Synopsis
  • A study was conducted on patients with atrial fibrillation who had an ischemic stroke while using nonvitamin K antagonist oral anticoagulants to determine rates and risk factors for recurrent ischemic and bleeding events.
  • Over an average follow-up of about 15 months, 15.5% of the 1,240 patients experienced 207 events, including ischemic strokes and major bleeding incidents, with specific risk factors identified for each type of event.
  • The rates of ischemic and bleeding events did not significantly differ between patients who changed their anticoagulant treatment and those who continued with it.
View Article and Find Full Text PDF
Article Synopsis
  • re! Since I don't have access to the specific text or figure you're referring to, I can't provide a direct synopsis of it. However, you can share the main points or information from the text, and I can help create a summary based on that. Just let me know!
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the risks of recurrent ischemic events and severe bleeding in patients with acute posterior ischemic stroke (PS) and atrial fibrillation (AF) in relation to oral anticoagulant therapy (OAT) and timing of initiation.
  • Researchers compared outcomes in 473 patients with PS to 1997 patients with anterior stroke (AS), focusing on events within 90 days of the initial stroke.
  • Findings indicated that both PS and AS patients had similar risks of ischemic or hemorrhagic events at 90 days, regardless of when OAT was initiated.
View Article and Find Full Text PDF

Background: In this randomized trial, currently utilized standard treatments were compared with enoxaparin for the prevention of venous thromboembolism (VTE) in patients with intracerebral hemorrhage (ICH).

Methods: Enoxaparin (0.4 mg daily for 10 days) was started after 72 h from the onset of ICH.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates when it's best to start oral anticoagulants after an ischemic stroke caused by atrial fibrillation, particularly focusing on patients who received thrombolysis or thrombectomy.
  • It combines data from two studies conducted between 2012 and 2016, analyzing patients treated with either Vitamin K antagonists or non-vitamin K oral anticoagulants for secondary stroke prevention.
  • Among 2159 patients included, the timing for starting anticoagulants was similar for those treated with reperfusion therapies and those not treated, with low rates of stroke or bleeding complications observed within 90 days.
View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates ischemic cerebrovascular events in patients with nonvalvular atrial fibrillation (AF) who are being treated with non-vitamin K antagonist oral anticoagulants (NOACs) to identify risk factors and understand the underlying mechanisms.
  • - The research involved 713 patients who experienced ischemic strokes or transient ischemic attacks while on NOACs, and 700 who did not, revealing significant associations between these events and factors like low NOAC dosage, atrial enlargement, hyperlipidemia, and higher CHADS-VASc scores, which indicate greater stroke risk.
  • - Findings suggest that while most strokes in this population were of cardioembolic origin, other factors such as being older,
View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from 1,810 patients, discovering that 20% underwent this bridging therapy, and found that bridged patients had worse outcomes, with a higher rate of ischemic events and major bleeding.
  • * The results indicate that bridging therapy significantly raises the risk of early complications compared to patients who did not receive it, prompting a reevaluation of its common use in clinical practice.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined the link between types of atrial fibrillation (paroxysmal vs. sustained) and the occurrence of early ischaemic recurrences after an acute stroke in patients.
  • Out of 2150 patients, those with sustained atrial fibrillation experienced a higher percentage of early ischaemic recurrences (6.2%) compared to those with paroxysmal atrial fibrillation (3.3%).
  • However, after considering other health risks, sustained atrial fibrillation did not show a significantly increased risk for early recurrence, suggesting that other factors may be more influential.
View Article and Find Full Text PDF

Background In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation ( HT ). The aims of this study were to evaluate in consecutive patients with acute stroke and atrial fibrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT , (3) the association of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days. Methods and Results HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after stroke onset.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the optimal timing for administering non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation, focusing on early recurrence of stroke and major bleeding within 90 days post-treatment.
  • A total of 1,127 patients participated, with diverse treatment groups receiving dabigatran, rivaroxaban, or apixaban; results revealed a low incidence of early recurrence (2.8%) and major bleeding (2.4%).
  • Patients starting NOACs within 2 days of stroke had higher rates of complications (12.4% composite rate), compared to delayed initiation (3-14 days had 2.1%, and >14 days
View Article and Find Full Text PDF

Background And Purpose: Public campaigns to increase stroke preparedness have been tested in different contexts, showing contradictory results. We evaluated the effectiveness of a stroke campaign, designed specifically for the Italian population in reducing prehospital delay.

Methods: According to an SW-RCT (Stepped-Wedge Cluster Randomized Controlled Trial) design, the campaign was launched in 4 provinces in the northern part of the region Emilia Romagna at 3-month intervals in randomized sequence.

View Article and Find Full Text PDF

Background: Systematic reviews call for well-designed trials with clearly described intervention components to support the effectiveness of educational campaigns to reduce patient delay in stroke presentation. We herein describe the systematic development process of a campaign aimed to increase stroke awareness and preparedness.

Methods: Campaign development followed Intervention Mapping (IM), a theory- and evidence-based tool, and was articulated in two phases: needs assessment and intervention development.

View Article and Find Full Text PDF
Article Synopsis
  • Atrial fibrillation increases stroke risk, especially in women, who tend to have worse outcomes than men; this study assesses sex differences in stroke patients with atrial fibrillation regarding risk factors, treatments, and outcomes.
  • Data from the RAF-study, involving 1029 patients, revealed women were younger and less likely to receive anticoagulant therapy both before and after stroke compared to men, despite similar timing for starting treatment.
  • At 90 days post-stroke, more women were disabled or deceased (57.7%) compared to men (41.1%), highlighting a significant disparity in outcomes related to treatment patterns.
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to explore how the prestroke CHADS-VASc score, which assesses stroke risk in patients with atrial fibrillation (AF), relates to the severity of strokes and outcomes like disability and mortality after 90 days.
  • - Researchers analyzed data from 1,020 patients with acute ischemic strokes and found that a higher prestroke CHADS-VASc score correlated with more severe strokes at admission and worse functional outcomes 90 days later.
  • - The findings suggest that, for patients with AF, a high CHADS-VASc score not only indicates a greater stroke risk but is also linked to increased stroke severity and higher rates of disability and death after three months.
View Article and Find Full Text PDF

Background And Purposes: This study was designed to derive and validate a score to predict early ischemic events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation.

Methods: The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in prospective series between January 2012 and March 2014. Older age (hazard ratio 1.

View Article and Find Full Text PDF

Background: Pre-hospital delay in acute stroke is critical to the administration of thrombolysis and affects patients' clinical outcome. In this study, the impact of pre-hospital delay on the outcome of ischemic stroke was investigated in an Italian cohort of patients who did not receive thrombolysis.

Methods: Data from a cohort of 1847 patients, suffering from first-ever ischemic stroke and referred to an in-hospital clinical pathway were analyzed retrospectively.

View Article and Find Full Text PDF

Anticoagulant therapy is recommended for the secondary prevention of stroke in patients with atrial fibrillation (AF). T he identification of patients at high risk for early recurrence, which are potential candidates to prompt anticoagulation, is crucial to justify the risk of bleeding associated with early anticoagulant treatment. The aim of this study was to evaluate in patients with acute ischemic stroke and AF the association between findings at trans-thoracic echocardiography (TTE) and 90 days recurrence.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the timing of anticoagulation therapy in patients with acute cardioembolic stroke and atrial fibrillation, focusing on risks for recurrent ischemic events and severe bleeding.
  • Out of 1029 patients, 12.6% experienced adverse events within 90 days, with factors like CHA2DS2-VASc score and type of anticoagulant affecting outcomes.
  • Starting anticoagulants 4 to 14 days after stroke onset is linked to a significant reduction in complications compared to starting before 4 days or after 14 days.
View Article and Find Full Text PDF

Background: Assessing the level of public stroke awareness is a prerequisite for development of community educational campaigns aimed at reducing prehospital delay of stroke patients. The Stroke Action Test (STAT) is a validated instrument specifically developed in the United States with the objective to assess the public's readiness to respond to stroke. Our purpose was to perform the cross-cultural adaptation of the original version of STAT to be applied to the Italian population.

View Article and Find Full Text PDF

The modified Charlson Comorbidity Index (MCCI) has been proposed as a tool for adjusting the outcomes of stroke for comorbidity, but its validity in such a context has been evaluated in only a few studies and needs to be further explored, especially in elderly patients. We aimed to retrospectively assess the validity of the MCCI as a predictor of the short-term outcomes in a cohort of 297 patients with first-ever ischemic stroke, older than 60 years, and managed according to a clinical pathway. The poor outcome (PO) at 1 month, defined as a modified Rankin Scale score of 3-6, was the primary end point.

View Article and Find Full Text PDF

Background: Stroke outcome has been reported as worse in women, especially in terms of disability. As for mortality, the data are conflicting, with some reports suggesting a female advantage. Our objective was to explore such issues in an Italian cohort of patients managed by a standardized clinical pathway (CPW) and, as such, homogeneous in terms of clinical management.

View Article and Find Full Text PDF

The hormone-replacement therapy for menopause has recently become matter of debate, especially after the first large randomized controlled trials failed to confirm the potential benefits on cardiovascular risk suggested by previous observational studies. On the contrary, the treatment has tuned out as to be potentially harmful, increasing the risk of stroke and of venous thromboembolism, without any benefit on coronary heart disease. Some factors, such as cardiovascular comorbidity, age and the time of treatment initiation since menopause, influence the clinical response to HRT, so that it can be considered relatively safe only in younger women, asymptomatic for cardiovascular disease and within 10 years from menopause.

View Article and Find Full Text PDF

During the last decade, a significant body of evidence has accumulated, indicating that the declining activity of the GH-IGF-I axis with aging might play a role in the development of frailty and in several pathological conditions commonly seen during aging, such as atherosclerosis, cardiovascular disease, and cognitive decline. GH therapy has become widely popular as antiaging therapy in order to counteract the age-related decline in muscle mass and strength and the increase in fat mass. However there are only few proven beneficial effects of GH therapy in healthy elderly subjects and its use remains highly controversial in the scientific community.

View Article and Find Full Text PDF

Objectives: To assess how much of the excess risk of poor outcome from stroke in people aged 80 and older aging per se explains, independent of other prognostic determinants.

Design: Cohort, observational.

Setting: University hospital.

View Article and Find Full Text PDF